Loading…

Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

Saved in:

Bibliographic Details
Published in:	The Journal of clinical investigation 2024-10, Vol.134 (20), p.1-3
Main Authors:	Morgan, Sarah J, Coulter, Ellis, Betts, Hannah L, Solomon, George M, Clancy, John P, Rowe, Steven M, Nichols, David P, Singh, Pradeep K
Format:	Article
Language:	English
Subjects:	Adaptation Adolescent Adult Aminophenols - therapeutic use Bacteria Benzodioxoles - therapeutic use Child Cystic fibrosis Cystic Fibrosis - drug therapy Cystic Fibrosis - genetics Cystic Fibrosis Transmembrane Conductance Regulator Dosage and administration Drug Combinations Drug therapy Drug therapy, Combination Female Health aspects Humans Indoles - therapeutic use Infections Ivacaftor Lung diseases Male Pathogens Physiological aspects Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology Pyrazoles - therapeutic use Pyridines - therapeutic use Pyrroles - therapeutic use Pyrrolidines Quinolines Quinolones - therapeutic use Research Letter
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!